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Abstract
Background Although health technology assessment
(HTA) systems base their decision making process either
on economic evaluations or comparative clinical benefit
assessment, a central aim of recent approaches to value
measurement, including value based assessment and pric-
ing, points towards the incorporation of supplementary
evidence and criteria that capture additional dimensions of
value.
Objective To study the practices, processes and policies of
value-assessment for new medicines across eight European
countries and the role of HTA beyond economic evaluation
and clinical benefit assessment.
Methods A systematic (peer review and grey) literature
review was conducted using an analytical framework
examining: (1) ‘Responsibilities and structure of HTA
agencies’; (2) ‘Evidence and evaluation criteria considered
in HTAs’; (3) ‘Methods and techniques applied in HTAs’;
and (4) ‘Outcomes and implementation of HTAs’. Study
countries were France, Germany, England, Sweden, Italy,
Netherlands, Poland and Spain. Evidence from the litera-
ture was validated and updated through two rounds of
feedback involving primary data collection from national
experts.
Results All countries assess similar types of evidence;
however, the specific criteria/endpoints used, their level of
provision and requirement, and the way they are incorpo-
rated (e.g. explicitly vs. implicitly) varies across countries,
with their relative importance remaining generally
unknown. Incorporation of additional ‘social value judge-
ments’ (beyond clinical benefit assessment) and economic
evaluation could help explain heterogeneity in coverage
recommendations and decision-making.
Conclusion More comprehensive and systematic assess-
ment procedures characterised by increased transparency,
in terms of selection of evaluation criteria, their importance
and intensity of use, could lead to more rational evidence-
based decision-making, possibly improving efficiency in
resource allocation, while also raising public confidence
and fairness.
Keywords Health technology assessment (HTA)  Value
assessment  Innovative medicines  High cost medicines 
Pharmaceutical policy  European Union  Systematic
review  Expert consultation
JEL Classification I (Health, Education, and Welfare)  I1
(Health)  I10 (General)  I11 (Analysis of Health Care
Markets)  I18 (Government Policy; Regulation; Public
Health)
Background
Current value assessment and appraisal approachesofmedical
technologies using economic evaluation or adopting com-
parative clinical benefit assessment in order to inform cover-
age decisions and improve efficiency in resource allocation
have been subject to criticism for a number of reasons.
Electronic supplementary material The online version of this
article (doi:10.1007/s10198-017-0871-0) contains supplementary
material, which is available to authorized users.
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Most health technology assessment (HTA) systems base
their decision-making process on cost per outcome metrics
of economic evaluations such as, for example, the cost per
quality adjusted life year (QALY) [1]. However a key
limitation of the QALY approach is the inadequacy of
capturing social value [2–4]. It is clear that a central aim of
more recent approaches to value measurement, including
value-based assessment and value-based pricing, involves
the incorporation of additional parameters capturing other
dimensions of value into the overall valuation
scheme [5, 6]. Although a number of additional criteria
beyond scientific value judgements are considered to assess
the evidence submitted and inform coverage decisions in
different HTA settings [7], their use remains implicit or ad
hoc rather than explicit and systematic.
Another drawback is caused by the way in which value
is assessed and appraised, often resulting in unexplained
heterogeneity of coverage decisions across settings even
for the same drug-indication pair [8–14]. Although some of
this decision heterogeneity could be justified on the
grounds of different budget constraints and national pri-
orities, inconsistencies in medicines’ eligibility for reim-
bursement across countries can give rise to an international
‘post-code’ lottery for patient access, even in the same
geographical region and can have important implications
for equity and fairness, especially when differences remain
unexplained [11]. Several studies have acknowledged the
need for well-defined decision-making processes that are
fairer and more explicit [15–17]. By ensuring ‘account-
ability for reasonableness’ and providing a better under-
standing of the rationale behind decision-making, decisions
will also have enhanced legitimacy and acceptability
[12, 18].
By reviewing and synthesising the evidentiary require-
ments (both explicit and implicit), the methods and tech-
niques applied and how they contribute to decision-making,
the objective of this study is to provide a critical review of
value assessment and appraisal methods for new medicines,
including the evaluation criteria employed across a number
of jurisdictions in Europe deploying explicit evaluation
frameworks in their HTA processes. More specifically, the
study seeks to determine whether HTA processes incorpo-
rate additional criteria beyond economic evaluation or clin-
ical benefit assessment, and, if so, which ones and how they
inform coverage recommendations. To date no study has
provided a similar review and analysis of HTA policies and
practices for innovativemedicines across different European
countries to this extent. In fulfilling the above aims, the next
section outlines the methods and includes the components of
the analytical framework adopted for this purpose; subse-
quently, the evidence collected from eight European coun-
tries is presented and discussed, before presenting the policy
implications.
Methods
We outline and propose a conceptual framework to facilitate
the systematic review of HTA processes and capture their
salient features across settings following previous evidence
[19]. Based on that, we collected the relevant evidence, rely-
ing onboth primary and secondary sources. The evidence base
covered eight EUMember States that have arms-length HTA
agencies and recognisedHTAprocesses. The study took place
in the context ofAdvance-HTA, anEU-funded project aiming
to contribute to advances in the methods and practices for
HTA in Europe and elsewhere [20].
Secondary sources of evidence comprised a systematic
review of the country-specific value-assessment peer review
literature using an analytical framework to investigate the
practices, processes and policies of value-assessment and their
impact, as observed in the study countries.
Evidence from the literaturewas validated bymeans of two
rounds of feedback involving primary data collection: the first
was from Advance-HTA consortium partners [20], while the
second involved a detailed validation of the study’s results by
national experts following the incorporation of all literature
results and feedback from Advance-HTA partners.
Analytical framework outlining the value
assessment and appraisal characteristics of HTA
systems
Existing frameworks for analysing and classifying coverage
decision-making systems for health technologies were
reviewed and adjusted according to the needs of the current
examination, which focuses on the assessment and appraisal
stages of the coverage review procedure from the HTA
agency’s or institution’s point of view, without having any
special interest on the decision outcomes per se [21–23].
The main value assessment and appraisal characteristics
necessary to outline the practices and processes in the
different countries of interest as reflected through
their national HTA agencies were classified using an ana-
lytical framework consisting of four key components, each
having a number of different sub-components: (1) ‘Re-
sponsibilities and structure of HTA agencies’; (2) ‘Evi-
dence and evaluation criteria considered in HTAs’; (3)
‘Methods and techniques applied in HTAs’; and (4) ‘Out-
comes and implementation of HTAs’. These were consid-
ered to be the main components needed in order to
sufficiently capture the features of the different HTA
systems.
In the context of this study, the second component was
more extensively examined because a key subject of our
investigation was to identify and analyse any additional
concerns and evaluation criteria beyond those informing
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economic evaluations or clinical benefit assessment. The
sub-components of the main components are described
below and are shown in Fig. 1.
Responsibilities and structure of HTA agencies
The first component considers the operational characteris-
tics of national HTA agencies. It includes details about the
function and responsibilities of HTA agencies, the relevant
committees within agencies tasked with assessment and
appraisal, details on the topic selection process, and whe-
ther methodological guidelines exist for the conduct of
pharmacoeconomic analysis.
Evidence and evaluation criteria considered in HTAs
This component relates to the types of evidence evaluated and
the particular evaluation criteria considered. Generally, the
assessed evidence can be classified into features relating to the
disease (indication) under consideration, or into characteris-
tics relating to the technology being assessed. The former is
reflected through the ‘burden of disease’ (BoD), i.e. the
impact that the disease has, which depends mainly on the
severity of the disease and the unmet medical need. The latter
can be classified into clinical benefit (mainly therapeutic
impact and safety considerations), innovation (e.g. clinical
novelty and nature of treatment), and socioeconomic impact
(e.g. public health impact, productivity loss impact). Other
important characteristics relate to efficiency (e.g. cost-effec-
tiveness, cost), ethical/equity considerations, accepted data
sources, and relative importance (i.e. weighting) of the
evidence.
Methods and techniques applied in HTAs
This component is associated with the evaluation methods
and techniques used. In terms of the analytical methods
applied (i.e. comparative efficacy/effectiveness, type of
economic evaluation), methodologies differ based on their
outcome measure and their elicitation technique, the choice
of comparator(s) and the perspective adopted. In relation to
the clinical evidence used to populate the analysis, crucial
details involve accepted or preferred data sources (i.e.
study designs), data collection approaches (e.g. require-
ment for systematic literature reviews) and synthesis (e.g.
suggestion for meta-analysis) of the data. In terms of
resources used, important considerations include the types
of costs and data sources. For both clinical outcomes and
costs, discount rate(s) applied and time horizons assumed
are included, together with the existence of any explicit or
implicit willingness-to-pay (WTP) thresholds on cost-ef-
fectiveness based on which recommendations are made.
Outcomes and implementation of HTAs
The final component relates to the outcomes of the evaluation
procedures and their implementation. Key characteristics
include the public availability of the evaluation report; the
policy implications ofwhether and howoutcomes are applied
in practice (e.g. pricing vs. reimbursement); the usage of any
access restrictions; how decisions are disseminated and
implemented; whether appeal procedures are available; and
the frequency of any recommendation revisions.
Systematic literature review
The systematic literature review methodology was based on
the Centre for Reviews and Dissemination (CRD) guidance
for undertaking systematic reviews in health care [24].
Inclusion criteria (country selection and study period)
The study countries (and the respective HTA agencies)
were France (Haute Autorite´ de Sante´, HAS), Germany
Responsibilities & 
structure
Evidence & 
evaluation 
criteria 
considered
Methods & 
techniques 
applied
Function 
Expert 
committee 
Topic selection 
Guidelines 
Burden of 
disease 
Therapeutic 
Innovation 
Socioeconomic 
Efficiency 
Others 
Analysis method 
Clinical evidence 
Resources/ costs 
Discounting 
Time horizon 
Thresholds 
Public 
availability 
Policy 
implication 
Access 
restrictions 
Dissemination 
Outcomes &  
implementation
Fig. 1 Main components and sub-components of the analytical framework applied
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(Institut fu¨r Qualita¨t und Wirtschaftlichkeit im Gesund-
heitswesen, IQWiG), Sweden (Tandva˚rds- och
la¨kemedelsfo¨rma˚nsverket, TLV), England (National Insti-
tute for Health and Care Excellence, NICE), Italy1
(Agenzia Italiana del Farmaco, AIFA), the Netherlands
[Zorginstituut Nederland, ZIN (formerly College voor
zorgverzekeringen, CVZ)], Poland (The Agency for Health
Technology Assessment and Tariff System, AOTMiT) and
Spain [Red de Agencias de Evaluacio´n de Tecnologı´as
Sanitarias y Prestaciones del Sistema Nacional de Salud
(RedETS) and the Interministerial Committee for Pricing
(ICP)].2 The study countries were selected because of their
variation in health system financing (tax-based vs. social
insurance-based), the organisation of the health care system
(central vs. regional organisation), the type of HTA in
place (predominantly economic evaluation vs. predomi-
nantly clinical benefit assessment), and the perspective
used in HTA (health system vs. societal), so that the sample
is representative of different health systems and HTA
approaches across Europe.
The study period for inclusion of relevant published
studies was from January 2000 to January 2014, with
article searches taking place in February 2013 in the first
instance and an update taking place at the end of January
2014. The year of 2000 was selected as the start date
because the HTA activity of most countries started then or
was significantly expanded in scope since then. Feedback
from the Advance-HTA consortium partners was provided
in August 2014. Additional input, including the most recent
updates on national HTA processes, was collected from
HTA experts and national competent authorities between
March and May 2016.
Identification of evidence
Two electronic databases (MEDLINE—through PubMed
resource—and the Social Science Citation Index—through
the Web of Science portal) were searched for peer-reviewed
literature only using a search strategy for English articles
published up until the time of the literature search (including
all results from the oldest to the latest available) using the
following keywords: ‘health technology assessment ?
pharmaceuticals’; ‘health technology assessment ?
methodologies’; ‘value assessment ? pharmaceuticals’;
and ‘value assessment ? methodologies’. Furthermore,
reference lists from the studies selected were screened (see
following section), retrieving any additional studies cited
that could be of relevance. Finally, grey literature was
searched including published guidelines from the HTA
agencies available online through each agency’s website.
Study selection and data extraction
Articles were selected according to a four-stage process as
outlined in Fig. 2 [24]. In the first stage, all titles and
abstracts were reviewed, with abstracts not relevant to the
topic excluded; where content relevance could not be
determined, articles were passed through to the next stage.
In the second stage, all relevant abstracts were assessed
against a number of pre-determined selection criteria by
two of the authors; these criteria included: (1) language
(only English articles were included), (2) study country
(only studies examining the eight countries of interest
were included), (3) study context (only national coverage
HTA perspectives were included), (4) study type (product-
specific technology appraisal reports were excluded), (5)
record type (conference proceedings or titles with no
abstracts available were excluded). In the third stage, full
articles for all abstracts meeting the eligibility criteria were
retrieved; in addition, relevant studies identified from ref-
erence screening and grey literature, including published
guidelines from HTA agencies, were incorporated (non-
English articles cited by English documents were included
in this stage). Finally, in the fourth stage, full articles were
reviewed and relevant data were extracted. An Excel
template listing the value assessment and appraisal char-
acteristics (categories and sub-categories) of interest was
used for data extraction. Data were extracted in free text
form, with no limitations on the number of free text fields,
and as little categorisation of data as possible, in order to
avoid loss of information. The lead author extracted the
data while the other authors independently checked the
extracted templates for completeness and accuracy.
Expert consultation
Upon consultation of the preliminary results with the
partners of the Advance-HTA consortium, it became
obvious that in a few cases (primarily for France and to a
lesser degree for Sweden), the evidence from the peer
review literature was outdated and did not reflect actual
practices, being even contradictory in some cases. As a
result, we solicited comments and feedback from the
1 Other HTA agencies exist on regional level (e.g. UVEF is
responsible for HTAs in the Veneto region).
2 RedETS is the Spanish Network of regional HTA agencies
coordinated by Institutde Salud Carlos III (ISCIII) and could be
regarded as the National HTA advisory body at federal level.
However, at this (federal) level it does not assess pharmaceuticals, but
mostly non-drug health technologies, such as screening programmes
and medical devices. Although the ICP, led by the Direccio´n General
de Farmacia under the Ministry of Health, is the committee
responsible for the assessment of drugs, producing mandatory
decisions at federal level regarding the reimbursement and pricing
of pharmaceuticals, the vast majority of economic evaluations for
drugs are conducted at autonomous community level by regional
HTA agencies.
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consortium partners in order to update and supplement the
information extracted from the systematic review. In a final
step, all updated results tables were shared with HTA
experts in the study countries, who were asked to review
and validate the outputs of the study. Experts (n = 18)
were affiliated with academic or research institutions (36%
Abstracts identified 
and screened 
= 2778  
Excluded (not relevant) = 
2523 
Abstracts potentially 
relevant to the topic of 
interest 
= 255
Excluded (inclusion criteria not 
satisfied) =  
125 
Full documents retrieved and 
assessed for eligibility 
= 148  
Selection of studies based on relevance of their 
content, i.e. information on value assessment 
systems’ characteristics and their performance 
Inclusion/exclusion of studies 
based on the following criteria: 
1) Language 
2) Country  
3) Context
4) Study type 
5) Record type 
Documents meeting inclusion 
criteria 
=101  
Excluded (no useful content, 
inclusion criteria not satisfied, or 
duplicate publication) =  
47
Selection of studies based on 
their content and their 
eligibility  
Abstracts meeting the  
eligibility criteria 
= 130  
Additional relevant 
documents identified 
from references screening 
and grey literature were 
incorporated 
Fig. 2 Flow chart of literature review process
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of total) and national competent authorities, such as HTA
agencies or payer bodies (64% of total), and provided
further evidence and guidance, including—in some cases—
additional literature sources outside the originally selected
review period, if appropriate. Expert input from these two
rounds of consultation are quoted as ‘personal communi-
cation’ from the Advance-HTA project [25].
Results
Figure 2 shows a flow chart of the review process and the
respective number of articles in each stage. In total, 2778
potentially eligible peer-reviewed article listings were
identified in the electronic databases; of these 255 articles
were identified as potentially useful and were read in full.
A total of 130 articles met the eligibility criteria, and an
additional 18 articles were identified as possibly relevant
through reference screening or as grey literature. The
content of 101 articles from the literature review was
finally used to inform the findings (Supplementary
Appendix 1). An additional five studies were identified
during the expert consultation process and were taken into
consideration in discussing and interpreting the results
(Supplementary Appendix 2).
Responsibilities and structure of national HTA
agencies
Across the study countries, HTA agencies exist mainly in
the form of autonomous governmental bodies, having
either an advisory or regulatory function. Usually, a tech-
nical group is responsible for early assessment of the evi-
dence following which an expert committee appraises the
request for coverage and produces recommendation(s) for
the final decision body.
The topic selection process is generally not entirely
transparent, with the belief that most agencies predomi-
nantly assess new medical technologies that are expensive
and/or with uncertain benefits. In some cases, topic selec-
tion is not applicable as all technologies that apply for
reimbursement need to be assessed.
In all study countries, with the exception of Italy and
Spain, official country-specific pharmacoeconomic
guidelines for the evaluation process are available,
mainly concerning methodological and reporting issues
[26, 27]. In England, in addition to the evaluation pro-
cess, guidelines also exist for the purpose of application
submission requirements, including the description of
key principles of the appraisal methodology adopted by
NICE [27]. For all countries, application of the guide-
lines is recommended. It is worth clarifying that
although some of the HTA agencies tend to focus on
medicines, others evaluate all types of health care
interventions; in this case the term ‘‘pharmacoeconomic’’
might not be adequately representative of the types of
guidelines in place, in which case they could be referred
to as ‘‘methods for HTA’’ as in the case of NICE. A
summary of the responsibilities and structure of the
national HTA agencies in the study countries is pre-
sented in Table 1.
Evidence and evaluation criteria considered
in HTAs
Generally all countries assess the same groups of evidence,
however the individual parameters considered and the way
they are evaluated differ from country to country. All
countries acknowledge the consideration of a wide variety
of data sources including scientific studies (e.g. clinical
trials, observational studies), national statistics, clinical
practice guidelines, registry data, surveys, expert opinion
and other evidence from pharmaceutical manufacturers
[28]. A summary of the evidence and the evaluation criteria
under consideration across the study countries is presented
in Table 2.
Evaluation principles and their relevance to priority
setting
In France, the assessment of the product’s medical benefit or
medical service rendered (Service Me´dical Rendu, SMR),
and improvement of medical benefit (Ame´lioration du Ser-
vice Me´dical Rendu, ASMR), determine a new drug’s
reimbursement and pricing respectively. As of October
2013, economic criteria have been introduced with the
Commission for Economic Evaluation and Public Health
(CEESP) evaluating the cost-effectiveness (without a cost-
effectiveness threshold in place) of products assessed to have
an ASMR I, II or III that are likely to impact social health
insurance expenditures significantly (total budget impact
greater than EUR 20 million); results are used by the Eco-
nomic Committee for Health Products (CEPS) in its price
negotiations with manufacturers [29]. Nevertheless, and
under this current framework, these economic evaluations do
not have the same impact on price negotiation as does the
ASMR, which is linked directly to pricing. Instead, the role
of economic evaluations is consultative in this process.
In Germany, the new Act to Reorganize the Pharma-
ceuticals Market in the Statutory Health Insurance (SHI)
System [Gesetz zur Neuordnung des Arzneimittelmarktes
in der gesetzlichen Krankenversicherung (AMNOG)] came
into effect on 1 January 2011. Since then, all newly
introduced drugs are subject to early benefit assessment.
A. Angelis et al.
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Pharmaceutical manufacturers have to submit a benefit
dossier for evaluation by the IQWiG. A final decision is
made by the Federal Joint Committee (Gemeinsamer
Bundesausschuss, G-BA). Benefit for new drugs encom-
passes the ‘‘patient-relevant therapeutic effect, specifically
regarding the amelioration of health status, the reduction of
disease duration, the extension of survival, the decrease in
side effects or the improvement of quality of life’’ [30].
Importantly, all new drugs are reimbursed upon marketing
authorisation, with benefit assessment mainly determining
price rather than reimbursement status.
In Sweden, a prioritisation framework with three
explicit factors for the allocation of resources is used: (1)
human dignity; (2) need and solidarity; and (3) cost-effi-
ciency [31–34]. However, in the specific legislation for the
pharmaceutical reimbursement system, human value is
generally seen as the overriding criterion with no clear
order between the other two [25]. Marginal benefit or
utility, according to which a diminishing cost-effectiveness
across indications and patient groups is explicitly recog-
nized, could be regarded as a fourth principle, mainly
meaning that there are no alternative treatments that are
significantly more suitable [31, 35, 36].
In England, the Secretary of State for Health has indi-
cated to NICE a number of factors that should be consid-
ered in the evaluation process: (1) the broad balance
between benefits and costs (i.e. cost-effectiveness); (2) the
degree of clinical need of patients; (3) the broad clinical
priorities for the NHS; (4) the effective use of resources
and the encouragement of innovation; and (5) any guidance
issued by the Secretary of State [37–39]. Decisions are
supposed to reflect societal values, underlined by a fun-
damental social value judgment [40].
The Netherlands focuses on four priority principles
when assessing medical technologies: (1) the ‘‘necessity’’
of a drug (severity/burden of disease) [41, 42]; (2) the
‘‘effectiveness’’ of a drug, according to the principles of
evidence-based medicine (EBM) [42, 43]; (3) the ‘‘cost-
effectiveness’’ of a drug [44]; and (4) ‘‘feasibility’’, i.e.
how feasible and sustainable it is to include the interven-
tion or care provision in the benefits package [45, 46].
In Italy, reimbursement of pharmaceuticals at the central
level is evaluated by AIFA’s Pricing and Reimbursement
Committee (CPR), which sets prices and reimbursement
conditions for drugs with a marketing authorisation based
on evidence of the following factors: the product’s thera-
peutic value (cost/efficacy analysis) and safety (pharma-
covigilance), the degree of therapeutic innovation, internal
market forecasts (number of potential patients and expec-
ted sales), the price of similar products within the same or
similar therapeutic category and product prices in other
European Union Member States [25]. In autonomous
regions, pricing and reimbursement of new drugs does notT
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require—except for very innovative drugs—epidemiologic
or economic evaluation studies nor assessment of cost
impact from the adoption of new drugs, as in other coun-
tries [25, 47].
An HTA in Poland is considered complete if it contains
(1) a clinical effectiveness analysis; (2) an economic
analysis; and (3) a healthcare system impact analysis. No
studies were available from the systematic review referring
to the evidence assessed or the different parameters con-
sidered by AOTMiT in Poland [48].
Finally, in Spain different regions apply a range of
different assessment requirements, but in general four main
evidence parameters are considered: (1) the severity of the
disease; (2) the therapeutic value and efficacy of the pro-
duct; (3) the price of the product; and (4) the budget impact
for the Spanish National Health System. The assessment is
usually a classification or a cost-consequences analysis that
does not take into account the long-term effects of a ther-
apy or the possible need of specialized care utilization.
Patient well-being and quality of life are also considered
[49].
Evaluation criteria taken into account in HTAs
Burden of disease In France, both the severity and the
existence of alternative treatments act as formal criteria,
thus essentially defining the concept of ‘need’ [41].
Severity is considered as part of the SMR, taking into
account symptoms, possible consequences, including
physical or cognitive handicap, and disease progression in
terms of mortality and morbidity [25]. The existence of
alternatives is scored against a binary scale (yes vs. no)
[50, 51].
In Germany, severity is considered as part of added
(clinical) benefit assessment. The clinical assessment is
based on ‘‘patient-relevant’’ outcomes, mainly relating to
how the patient survives, functions or feels, essentially
accounting for the dimensions of mortality, morbidity and
HRQoL [52].
In Sweden, severity of the condition and the availability
of treatments reflected through marginal benefit/utility as a
sub-principle appear to be two of the primary criteria for
priority-setting, with more severe indications being
explicitly prioritized via greater willingness to pay (WTP)
[31, 35, 36, 41].
In England, the degree of unmet clinical need is a formal
criterion taken into account, being reflected by the avail-
ability of alternative treatments [41, 53]. NICE acknowl-
edges that rarity plays a key role in the assessment of
orphans and NICE’s Citizens’ Council has stated that
society would be willing to pay more for rare and serious
diseases [54]. The severity of the disease is taken into
account mainly through the special status of life-extending
medicines for patients with short-life expectancy as
reflected through the issuing of supplementary advice of
life-extending end-of-life (EOL) treatments by NICE
[53, 55].
Severity of disease, availability of treatments, and
prevalence of the disease are generally considered across
the remaining countries, either explicitly or implicitly,
although not always as mandatory requirements by law but
just as good HTA practices (e.g. as in Poland for the case
of treatments availability) [25].
Therapeutic impact and safety Clinical evidence relating
to therapeutic efficacy and safety acts as the most important
formal criterion of the evaluation process in France [56].
The product’s SMR relates to the actual clinical benefit,
responding to the question of whether the drug is of suf-
ficient interest to be covered by social health insurance. It
takes into consideration the following criteria: (1) the
seriousness of the condition; (2) the treatment’s efficacy;
(3) side effects; (4) the product’s position within the ther-
apeutic strategy given other available therapies; and (5) any
public health impact [25, 27].
Similarly to France, in Germany all clinically relevant
outcomes are considered and final clinically meaningful
outcomes (e.g. increase in overall survival, reduction of
disease duration, improvement in HRQoL) are preferred
over surrogate and composite endpoints [27, 28, 52, 57,
58]. HRQoL endpoints are considered if measured using
validated instruments suited for application in clinical trials
[25, 30]. With regards to uncertainty, IQWiG ranks the
results of a study according to ‘‘high certainty’’ (random-
ized study with low bias risk), ‘‘moderate’’ (randomized
study with high bias risk), and ‘‘low certainty’’ (non-ran-
domized comparative study). The complete evidence base
is then assessed and a conclusion is reached on the prob-
ability of the (added) benefit and harm, graded according to
major added benefit, considerable added benefit, and minor
added benefit. Three additional categories are recognized:
non-quantifiable added benefit, no added benefit, and lesser
benefit [25, 52].
All types of clinically relevant outcomes are accepted in
Sweden, including final outcomes, surrogate endpoints, and
composite endpoints, with generic QoL endpoints being
preferred over disease-specific endpoints [25, 57]. Gener-
ally, all effects of a person’s health and QoL are supposed
to be considered as part of the assessment stage, including
treatment efficacy and side effects [35, 36, 56].
In England, data on all clinically relevant outcomes are
accepted with final clinical outcomes (e.g. life years
gained) and patient HRQoL being preferred over interme-
diate outcomes (e.g. events avoided) or surrogate endpoints
and physiological measures (e.g. blood glucose levels)
[57, 59–61]; particular outcomes of interest include
Using health technology assessment to assess the value of new medicines...
123
mortality and morbidity. Safety is addressed mainly
through the observation of adverse events [53]. Uncertainty
is addressed explicitly through quality of evidence,
implicitly through preference for RCTs, and indirectly by
rejecting a submission if evidence is not scientifically
robust.
Italy, the Netherlands, Poland and Spain include surro-
gate and composite endpoints in the analysis, in addition to
disease-specific quality of life endpoints. Therapeutic value
is the most critical criterion for reimbursement in the
Netherlands, as part of which patient preference data and
user friendliness may also be considered [43].
All countries take into consideration safety data to
reflect clinical harm, mainly in the form of the incidence
and severity of adverse events.
Innovation level In the French setting, clinical novelty is
considered by definition through the product’s ASMR
relating to its relative added clinical value, which informs
pricing negotiations [25]. Additional innovation charac-
teristics relating to the nature of the treatment (e.g. dif-
ferentiating between symptomatic, preventive and curative)
are also considered, but as a second line of criteria
[25, 56, 61, 62].
In Germany, clinical novelty is considered implicitly as
part of the consideration of added therapeutic benefit for
premium pricing. Ease of use and comfort (if relevant for
morbidity or side effects) can be reflected indirectly through
treatment satisfaction for patients, which can be considered
as an additional aspect but not as an explicit factor, similarly
to the nature of the treatment/technology [63].
In Sweden, innovation characteristics relating to the
added therapeutic benefit (only if it can be captured in the
CE analysis), as well as ease of use and comfort are
included in the assessment process [25, 41, 56, 61].
As reflected through NICE’s operational principles, the
encouragement of innovation is an important consideration
in England. By definition, the incremental therapeutic
benefit as well as the innovative nature of the technology
are formally taken into account as part of the product’s
incremental cost effectiveness ratio (ICER) [53].
Among the remaining countries, clinical novelty is
essentially considered in all countries; ease of use and
comfort might only be considered implicitly and informally
if at all, whereas there are mixed approaches in terms of a
treatment’s technology nature.
Socioeconomic impact In terms of socioeconomic
parameters, in France ‘expected’ public health benefit acts
as another explicit dimension via an indicator known as
public health interest (‘‘Inte´reˆt de Sante´ Publique’’, ISP),
which is assessed and scored separately by a distinct
committee as part of the SMR evaluation but not used often
[25, 41, 62, 64].
In Germany, public health benefit is not explicitly con-
sidered but only partially reflected through the requirement
from manufacturers to submit information on the expected
number of patients and patient groups for which an added
benefit exists, as well as costs for the public health system
(statutory health insurance) [25, 63]. All direct costs have
to be considered, including both medical and non-medical
(when applicable), whereas indirect costs are not a primary
consideration but can be evaluated separately if they are
substantial, with productivity losses due to incapacity being
included only on the cost side [65]. In turn, productivity
losses due to mortality are considered in the outcome only
on the benefit side (to avoid double counting). Budget
impact analysis (BIA) is mandatory and should include any
one-off investments or start-up costs required in order to
implement a new technology, with methodology and
sources clearly outlined [27, 65].
Among the other study countries, any public health
impact of the drug is usually considered, but not neces-
sarily in an explicit manner, whereas social productivity
might be reflected through the incorporation of indirect
costs, either explicitly or implicitly [25]. In England for
example, although productivity costs should be excluded,
cost of time spent on informal caregiving can be presented
separately if this care might otherwise have been provided
by the NHS or personal social services (PSS) [66].
Efficiency In France, up until now cost-effectiveness was
not acknowledged as an explicit or mandatory criterion, but
BIA, while not mandatory, is highly recommended [25].
Although the expert committee had been reluctant to use
cost-effectiveness criteria in the evaluation process
[56, 67], following a bylaw passed in 2012 (which took
effect in 2013) the role of economic evidence was
strengthened [51]. The CEESP gives an opinion on the
efficiency of the drug based on the ASMR of alternative
treatments.
In Germany, economic analysis [cost-benefit-analysis
(CBA)] is not standard practice in the evaluation, but,
rather, is optional and can be initiated if no agreement is
reached between sickness funds and the manufacturer on
the price premium, or if the manufacturer does not agree
with the decision of the G-BA regarding premium pricing
(added benefit); instead, BIA is mandatory (Advance-HTA,
2016). ‘Cost-effectiveness’ acts as one of the most
important formal evaluation criteria in Sweden. Parameters
having a socioeconomic impact, such as avoiding doctor
visits or surgery, productivity impact, and, in general,
savings on direct and indirect costs are also considered
[35].
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As already reflected through NICE’s working principles,
the relative balance between costs and benefits (i.e. value-
for-money), and the effective use of resources should be
taken into account in England (e.g. through the explicit
cost-effectiveness criterion) [37]. Some studies also sug-
gest that the impact of cost to the NHS in combination with
budget constraints (budget impact considerations) are taken
into account alongside the other clinical and cost-effec-
tiveness evidence [39, 67–70].
In the assessment process by ZIN, the cost-effective-
ness criterion follows that of the therapeutic value and
the cost consequences analysis. Cost-effectiveness is
only considered for drugs with added therapeutic value,
which are either part of a cluster and are reimbursed at
most at the cluster’s reference price, or are not reim-
bursed in the absence of possible clustering [43, 71]. The
Netherlands usually performs its own BIA, although
voluntary submission from the manufacturer is also an
option [43, 67].
All other study countries evaluate the efficiency of new
drugs through cost-effectiveness evaluation and BIA, but
this is not always mandatory or an explicit criterion in
value assessment and pricing/reimbursement negotiations.
Other types of evidence Additional explicit parameters
considered in France include the technology’s place in
the therapeutic strategy, mainly in relation to other avail-
able treatments (i.e. first-line treatment vs. second-line
treatment etc.), and the technology’s conditions of use
[25, 50, 51].
Germany is the only country that does not apply any
conditions of use in regards to specific sub-populations,
in principle reimbursing drugs across the whole indica-
tion spectrum as listed on the marketing authorisation
[25]. Nevertheless, recent IQWiG appraisals increasingly
focus on providing value assessments at sub-population
level.
As reflected through the ethical prioritisation framework
used by the Swedish TLV, the ethical considerations of
human dignity, need and solidarity act as principles for the
evaluations.
Besides the notion of clinical need as reflected through
NICE’s principles, other equity considerations include the
‘need to distribute health resources in the fairest way
within society as a whole’ and the aim of ‘actively tar-
geting inequalities’, both of which are explicitly mentioned
by NICE as principles of social value judgements [37].
Equality, non-discrimination, and autonomy are other
explicit ethical considerations [41].
The Netherlands also takes into consideration explicitly
ethical criteria based on egalitarian principles, such as
solidarity and affordability of the technology by individual
patients [25, 33, 41].
In terms of the remaining countries, conditions for use
may be placed in Italy, Poland and Spain, the therapy’s
place in therapeutic strategy considerations exist for Italy
and Spain, whereas ethical considerations are evident in
Italy and Poland (implicitly or indirectly). However, the
use of any additional explicit parameters may not be
transparent in these settings.
Synthesizing the evidence and taking into account all
factors: weights
It is not clear how all the factors discussed so far interact
with one another, what their relative importance is and
what the trade-offs are that HTA agencies are prepared to
make between them when arriving at recommendations
[70, 72]. For example, in France the weights of the
assessment parameters considered and the appraisal pro-
cess overall do not seem to be clear or transparent [56],
although the evidence that informs this judgment is dated
and may be contestable. In Spain, the assessment takes into
account mainly safety, efficacy, effectiveness, and acces-
sibility and it does not consider explicitly efficiency and
opportunity cost; still the way this is undertaken and the
weights of different criteria remain unknown [73]. All
countries consider a number of different data sources for
the assessment process, with randomised controlled trials
(RCTs) usually being the most preferred source for clinical
data.
HTA methods and techniques applied
Assuming the existence of an additional benefit (or lesser
harm) compared to existing treatment options, all coun-
tries with the exception of France and Germany are
adopting some type of economic evaluation, mainly cost
utility analysis (CUA) or cost-effectiveness analysis
(CEA), as the analytical tool to arrive at value-for-money
recommendations aiming at improving effiiency in
resource allocation; both France and Germany used to
apply a comparative assessment of clinical benefit as the
sole methodology, with economic evaluation progressively
becoming more important in France as of 2013 but in the
context of the existing method of assessment. A summary
of analytical methods and techniques applied as part of
HTA and their details is presented in Table 3.
Analytical methods
In Sweden and England the preferred type of economic
evaluation is CUA with cost per QALY gained being the
favoured health outcome measure, but CEA being also
accepted if there is supporting evidence to do so (as in the
case that the use of QALY for a particular case seems
Using health technology assessment to assess the value of new medicines...
123
T
a
b
le
3
H
T
A
m
et
h
o
d
s
an
d
te
ch
n
iq
u
es
ap
p
li
ed
F
ra
n
ce
(H
A
S
/C
E
E
S
P
a
)
G
er
m
an
y
(I
Q
W
iG
)
S
w
ed
en
(T
L
V
)
E
n
g
la
n
d
(N
IC
E
)
It
al
y
(A
IF
A
)
N
et
h
er
la
n
d
s
(Z
IN
)
P
o
la
n
d
(A
O
T
M
iT
)
S
p
ai
n
(R
ed
E
T
S
/I
S
C
II
I
o
r
IC
P
)
A
n
a
ly
si
s
m
et
h
o
d
M
et
h
o
d
s
C
o
m
p
ar
at
iv
e
ef
fi
ca
cy
/e
ff
ec
ti
v
en
es
s
(a
ls
o
C
E
A
,
C
U
A
)
C
B
A
b
u
t
al
so
C
U
A
an
d
C
E
A
(n
o
t
st
an
d
ar
d
p
ra
ct
ic
e)
C
U
A
(a
ls
o
C
E
A
,
C
B
A
)
C
U
A
(a
ls
o
C
E
A
,
C
M
A
)
C
M
A
,
C
E
A
,
C
U
A
,
C
B
A
b
C
E
A
,
C
U
A
,
n
o
C
M
A
C
o
st
-c
o
n
se
q
u
en
ce
s
an
al
y
si
s,
C
E
A
o
r
C
U
A
—
o
b
li
g
at
o
ry
,
C
M
A
(i
f
ap
p
li
ca
b
le
)
C
o
m
p
ar
at
iv
e
ef
fi
ca
cy
/
ef
fe
ct
iv
en
es
s,
C
M
A
,
C
E
A
,
C
U
A
,
C
B
A
c
P
re
fe
rr
ed
o
u
tc
o
m
e
m
ea
su
re
F
in
al
o
u
tc
o
m
e,
li
fe
y
ea
rs
(Q
A
L
Y
,
if
C
U
A
;
li
fe
y
ea
rs
,
if
C
E
A
)
P
at
ie
n
t
re
le
v
an
t
o
u
tc
o
m
e
(c
an
b
e
m
u
lt
id
im
en
si
o
n
al
)—
ef
fi
ci
en
cy
fr
o
n
ti
er
Q
A
L
Y
(W
T
P
,
if
C
B
A
)
Q
A
L
Y
(c
o
st
p
er
li
fe
y
ea
r
g
ai
n
ed
,
if
C
E
A
)
F
in
al
o
u
tc
o
m
e,
li
fe
y
ea
rs
(Q
A
L
Y
,
if
C
U
A
o
r
C
E
A
;
li
fe
y
ea
rs
,
if
C
E
A
)
E
ff
ec
ti
v
en
es
s
b
y
in
te
n
ti
o
n
-
to
-t
re
at
p
ri
n
ci
p
le
,
an
d
ex
p
re
ss
ed
in
n
at
u
ra
l
u
n
it
s—
p
re
fe
ra
b
ly
L
Y
G
o
r
Q
A
L
Y
Q
A
L
Y
o
r
L
Y
G
Q
A
L
Y
in
C
U
A
U
ti
li
ty
sc
o
re
s
el
ic
it
at
io
n
te
ch
n
iq
u
e
E
Q
-5
D
an
d
H
U
I3
,
fr
o
m
g
en
er
al
F
re
n
ch
p
o
p
u
la
ti
o
n
U
ti
li
ty
sc
o
re
s
fr
o
m
p
at
ie
n
ts
,
d
ir
ec
t
(e
.g
.
T
T
O
,
S
G
),
in
d
ir
ec
t
U
ti
li
ty
sc
o
re
s
fr
o
m
p
at
ie
n
ts
,
d
ir
ec
t
(e
.g
.
T
T
O
,
S
G
),
in
d
ir
ec
t
(E
Q
-5
D
)
U
ti
li
ty
sc
o
re
s
fr
o
m
g
en
er
al
E
n
g
li
sh
p
o
p
u
la
ti
o
n
,
d
ir
ec
t
(e
.g
.
T
T
O
,
S
G
),
in
d
ir
ec
t
(E
Q
-5
D
),
sy
st
em
at
ic
re
v
ie
w
B
o
th
d
ir
ec
t
an
d
in
d
ir
ec
t
(E
Q
-
5
D
)
el
ic
it
at
io
n
te
ch
n
iq
u
es
E
it
h
er
d
ir
ec
t
(T
T
O
,
S
G
,
V
A
S
),
o
r
in
d
ir
ec
t
(E
Q
-5
D
);
se
le
ct
io
n
sh
o
u
ld
b
e
ju
st
ifi
ed
D
ir
ec
t
o
r
in
d
ir
ec
t
u
ti
li
ty
sc
o
re
sd
U
ti
li
ty
sc
o
re
s
fr
o
m
g
en
er
al
S
p
an
is
h
p
o
p
u
la
ti
o
n
,
d
ir
ec
t
(e
.g
.
T
T
O
,
S
G
),
in
d
ir
ec
t
(E
Q
-5
D
)e
C
o
m
p
ar
at
o
r
U
su
al
ly
‘b
es
t
st
an
d
ar
d
o
f
ca
re
’
b
u
t
ca
n
b
e
m
o
re
th
an
o
n
ef
U
su
al
ly
‘b
es
t
st
an
d
ar
d
o
f
ca
re
’
b
u
t
ca
n
b
e
m
o
re
th
an
o
n
eg
U
su
al
ly
‘b
es
t
st
an
d
ar
d
o
f
ca
re
’
b
u
t
ca
n
b
e
m
o
re
th
an
o
n
eh
U
su
al
ly
‘b
es
t
st
an
d
ar
d
o
f
ca
re
’
b
u
t
ca
n
b
e
m
o
re
th
an
o
n
eI
U
su
al
ly
‘b
es
t
st
an
d
ar
d
o
f
ca
re
’
b
u
t
ca
n
b
e
m
o
re
th
an
o
n
ej
T
re
at
m
en
t
in
cl
in
ic
al
g
u
id
el
in
es
o
f
G
P
s;
if
n
o
t
av
ai
la
b
le
,
m
o
st
p
re
v
al
en
t
tr
ea
tm
en
t
‘B
es
t
st
an
d
ar
d
o
f
ca
re
’
w
h
ic
h
is
re
im
b
u
rs
ed
in
P
o
la
n
d
k
B
es
t
st
an
d
ar
d
o
f
ca
re
,
u
su
al
ca
re
an
d
/o
r
m
o
re
co
st
-
ef
fe
ct
iv
e
al
te
rn
at
iv
e
A. Angelis et al.
123
T
a
b
le
3
co
n
ti
n
u
ed
F
ra
n
ce
(H
A
S
/C
E
E
S
P
a
)
G
er
m
an
y
(I
Q
W
iG
)
S
w
ed
en
(T
L
V
)
E
n
g
la
n
d
(N
IC
E
)
It
al
y
(A
IF
A
)
N
et
h
er
la
n
d
s
(Z
IN
)
P
o
la
n
d
(A
O
T
M
iT
)
S
p
ai
n
(R
ed
E
T
S
/I
S
C
II
I
o
r
IC
P
)
P
er
sp
ec
ti
v
e
W
id
es
t
p
o
ss
ib
le
to
in
cl
u
d
e
al
l
h
ea
lt
h
sy
st
em
st
ak
eh
o
ld
er
sl
U
su
al
ly
st
at
u
to
ry
h
ea
lt
h
in
su
ra
n
tm
S
o
ci
et
al
C
o
st
p
ay
er
(N
H
S
)
o
r
so
ci
et
al
if
ju
st
ifi
ed
It
al
ia
n
N
at
io
n
al
H
ea
lt
h
S
er
v
ic
en
S
o
ci
et
al
(r
ep
o
rt
in
d
ir
ec
t
co
st
s
se
p
ar
at
el
y
)
T
h
e
p
u
b
li
c
p
ay
er
’s
p
er
sp
ec
ti
v
e,
p
u
b
li
c
p
ay
er
an
d
p
at
ie
n
t
(b
y
la
w
)
C
o
st
p
ay
er
(N
H
S
)
an
d
so
ci
et
al
(r
ar
el
y
u
se
d
),
an
d
th
ey
sh
o
u
ld
b
e
p
re
se
n
te
d
se
p
ar
at
el
y
S
u
b
g
ro
u
p
an
al
y
si
s
Y
es
(w
h
en
ju
st
ifi
ed
)
Y
es
Y
es
Y
es
Y
es
Y
es
Y
es
(i
f
n
ee
d
ed
,
b
u
t
d
ec
re
as
es
v
al
id
it
y
)
Y
es
C
li
n
ic
a
l
ev
id
en
ce
P
re
fe
rr
ed
st
u
d
y
d
es
ig
n
H
ea
d
-t
o
-h
ea
d
R
C
T
s;
o
th
er
d
es
ig
n
s
ac
ce
p
te
d
if
n
o
R
C
T
s
av
ai
la
b
le
H
ea
d
-t
o
-h
ea
d
R
C
T
s;
o
th
er
d
es
ig
n
s
ac
ce
p
te
d
in
th
e
ab
se
n
ce
o
f
R
C
T
s
H
ea
d
-t
o
-h
ea
d
R
C
T
s;
o
th
er
d
es
ig
n
s
ac
ce
p
te
d
if
n
o
R
C
T
s
av
ai
la
b
le
H
ea
d
-t
o
-h
ea
d
R
C
T
s;
o
th
er
d
es
ig
n
s
ac
ce
p
te
d
if
n
o
R
C
T
s
av
ai
la
b
le
H
ea
d
-t
o
-h
ea
d
R
C
T
s;
o
th
er
d
es
ig
n
s
ac
ce
p
te
d
if
n
o
R
C
T
s
av
ai
la
b
le
H
ea
d
-t
o
-h
ea
d
R
C
T
s
H
ea
d
-t
o
-h
ea
d
R
C
T
s;
o
th
er
d
es
ig
n
s
ac
ce
p
te
d
if
n
o
R
C
T
s
av
ai
la
b
le
H
ea
d
-t
o
-h
ea
d
R
C
T
s;
o
th
er
d
es
ig
n
s
ac
ce
p
te
d
if
n
o
R
C
T
s
av
ai
la
b
le
S
y
st
em
at
ic
li
te
ra
tu
re
re
v
ie
w
s
fo
r
co
ll
ec
ti
n
g
ev
id
en
ce
re
q
u
ir
ed
/c
o
n
d
u
ct
ed
b
y
re
g
u
la
to
r
Y
es
,
g
u
id
el
in
es
p
ro
v
id
ed
/y
es
,
in
F
re
n
ch
Y
es
/n
o
N
o
t
m
an
d
at
o
ry
Y
es
/y
es
Y
es
/y
es
Y
es
/y
es
Y
es
N
o
t
al
w
ay
so
M
et
a-
an
al
y
si
s
fo
r
p
o
o
li
n
g
ev
id
en
ce
N
o
t
sp
ec
ifi
ed
N
o
t
sp
ec
ifi
ed
fo
r
n
ew
d
ru
g
s
N
o
t
sp
ec
ifi
ed
Y
es
Y
es
Y
es
,
en
co
u
ra
g
ed
Y
es
N
o
p
D
at
a
ex
tr
ap
o
la
ti
o
n
Q
u
al
it
at
iv
e
o
n
ly
,
in
ab
se
n
ce
o
f
ef
fe
ct
iv
en
es
s
d
at
a
fo
rm
R
C
T
s
N
o
Q
u
an
ti
ta
ti
v
e,
b
o
th
in
ab
se
n
ce
o
f
R
C
T
ef
fe
ct
iv
en
es
s
d
at
a
an
d
in
ab
se
n
ce
o
f
lo
n
g
-t
er
m
ef
fe
ct
s
Q
u
al
it
at
iv
e
an
d
q
u
an
ti
ta
ti
v
e,
b
o
th
in
ab
se
n
ce
o
f
R
C
T
ef
fe
ct
iv
en
es
s
d
at
a
an
d
in
ab
se
n
ce
o
f
lo
n
g
-t
er
m
ef
fe
ct
s
Q
u
an
ti
ta
ti
v
e
Q
u
al
it
at
iv
e
in
ab
se
n
ce
o
f
R
C
T
ef
fe
ct
iv
en
es
s
d
at
a
Q
u
al
it
at
iv
e,
in
th
e
ab
se
n
ce
o
f
R
C
T
s
an
d
in
ab
se
n
ce
o
f
lo
n
g
-t
er
m
ef
fe
ct
s
P
o
ss
ib
le
if
n
ee
d
ed
b
u
t
n
o
t
re
co
m
m
en
d
ed
Q
u
an
ti
ta
ti
v
e,
in
th
e
ab
se
n
ce
o
f
ef
fe
ct
iv
en
es
s
d
at
a
R
es
o
u
rc
es
/c
o
st
s
T
y
p
es
D
ir
ec
t
m
ed
ic
al
,
d
ir
ec
t
n
o
n
-m
ed
ic
al
,
in
d
ir
ec
t
(b
o
th
fo
r
p
at
ie
n
t
an
d
ca
re
r)
D
ep
en
d
in
g
o
n
p
er
sp
ec
ti
v
e:
d
ir
ec
t
m
ed
ic
al
,
in
fo
rm
al
co
st
s,
p
ro
d
u
ct
iv
it
y
lo
ss
(a
s
co
st
s)
D
ir
ec
t
m
ed
ic
al
,
d
ir
ec
t
n
o
n
-m
ed
ic
al
,
in
d
ir
ec
t
(b
o
th
fo
r
p
at
ie
n
t
an
d
ca
re
r)
D
ir
ec
t
m
ed
ic
al
,
so
ci
al
se
rv
ic
es
D
ir
ec
t
co
st
s
o
n
ly
;
in
d
ir
ec
t
co
st
s
ca
n
b
e
ta
k
en
in
to
ac
co
u
n
t
in
a
se
p
ar
at
e
an
al
y
si
s
B
o
th
d
ir
ec
t
an
d
in
d
ir
ec
t
co
st
s
in
si
d
e
an
d
o
u
ts
id
e
th
e
h
ea
lt
h
ca
re
sy
st
em
D
ir
ec
t
m
ed
ic
al
co
st
s,
d
ir
ec
t
n
o
n
-
m
ed
ic
al
co
st
s
D
ir
ec
t
an
d
in
d
ir
ec
t
co
st
s
(o
n
ra
re
o
cc
as
io
n
s)
,
co
st
s
o
f
la
b
o
u
r
p
ro
d
u
ct
io
n
lo
ss
es
o
r
lo
st
ti
m
e,
in
fo
rm
al
ca
re
co
st
s
Using health technology assessment to assess the value of new medicines...
123
T
a
b
le
3
co
n
ti
n
u
ed
F
ra
n
ce
(H
A
S
/C
E
E
S
P
a
)
G
er
m
an
y
(I
Q
W
iG
)
S
w
ed
en
(T
L
V
)
E
n
g
la
n
d
(N
IC
E
)
It
al
y
(A
IF
A
)
N
et
h
er
la
n
d
s
(Z
IN
)
P
o
la
n
d
(A
O
T
M
iT
)
S
p
ai
n
(R
ed
E
T
S
/I
S
C
II
I
o
r
IC
P
)
D
at
a
so
u
rc
e/
u
n
it
co
st
s
D
ir
ec
t:
P
M
S
I
(P
ro
g
ra
m
m
e
d
e
M
e´d
ic
al
is
at
io
n
d
es
S
y
st
e`m
es
d
’I
n
fo
rm
at
io
n
)
In
d
ir
ec
t:
h
u
m
an
ca
p
it
al
co
st
in
g
,
fr
ic
ti
o
n
co
st
in
g
S
ta
tu
to
ry
h
ea
lt
h
in
su
ra
n
ce
,
fu
rt
h
er
co
n
si
d
er
at
io
n
s
d
ep
en
d
in
g
o
n
p
er
sp
ec
ti
v
e
ch
o
se
n
D
ru
g
s:
p
h
ar
m
ac
y
p
ri
ce
s
In
d
ir
ec
t:
h
u
m
an
ca
p
it
al
co
st
in
g
O
ffi
ci
al
D
o
H
li
st
in
g
V
ar
ie
ty
o
f
so
u
rc
es
q
R
ef
er
en
ce
p
ri
ce
s
li
st
sh
o
u
ld
b
e
u
se
d
V
ar
ie
ty
o
f
so
u
rc
es
r
O
ffi
ci
al
p
u
b
li
ca
ti
o
n
s,
ac
co
u
n
ts
o
f
h
ea
lt
h
ca
re
ce
n
tr
es
,
an
d
th
e
fe
es
ap
p
li
ed
to
N
H
S
se
rv
ic
e
p
ro
v
is
io
n
co
n
tr
ac
ts
D
is
co
u
n
ti
n
g
C
o
st
s
4
%
(u
p
to
3
0
y
ea
rs
)
an
d
2
%
af
te
r
3
%
3
%
3
.5
%
N
o
t
av
ai
la
b
le
(u
p
d
at
e
in
p
ro
g
re
ss
)
4
%
5
%
3
%
O
u
tc
o
m
es
4
%
(u
p
to
3
0
y
ea
rs
)
an
d
2
%
af
te
r
3
%
3
%
3
.5
%
N
o
t
av
ai
la
b
le
(u
p
d
at
e
in
p
ro
g
re
ss
)
U
n
d
er
re
v
ie
w
—
w
il
l
p
ro
b
ab
ly
b
e
se
t
at
sa
m
e
le
v
el
as
co
st
s
d
is
co
u
n
ti
n
g
3
.5
%
3
%
S
en
si
ti
v
it
y
an
al
y
si
s
0
%
,
3
%
(6
%
m
ax
)
0
–
5
%
0
–
5
%
0
–
6
%
N
o
t
av
ai
la
b
le
(u
p
d
at
e
in
p
ro
g
re
ss
)
N
o
t
o
b
li
g
at
o
ry
5
an
d
0
%
fo
r
co
st
s
an
d
o
u
tc
o
m
es
0
%
fo
r
o
u
tc
o
m
es
5
%
fo
r
co
st
ss
0
–
5
%
T
im
e
h
o
ri
zo
n
T
im
e
h
o
ri
zo
n
L
o
n
g
en
o
u
g
h
so
th
at
al
l
tr
ea
tm
en
t
o
u
tc
o
m
es
ca
n
b
e
in
cl
u
d
ed
A
t
le
as
t
th
e
av
er
ag
e
(c
li
n
ic
al
)
st
u
d
y
d
u
ra
ti
o
n
;
lo
n
g
er
fo
r
ch
ro
n
ic
co
n
d
it
io
n
s,
es
p
ec
ia
ll
y
if
li
fe
ti
m
e
g
ai
n
s
ar
e
ex
p
ec
te
d
;
sa
m
e
h
o
ri
zo
n
fo
r
co
st
s
an
d
b
en
efi
ts
T
im
e
n
ee
d
ed
to
co
v
er
al
l
m
ai
n
o
u
tc
o
m
es
an
d
co
st
s
L
o
n
g
en
o
u
g
h
to
re
fl
ec
t
an
y
d
if
fe
re
n
ce
s
o
n
o
u
tc
o
m
es
an
d
co
st
s
b
et
w
ee
n
te
ch
n
o
lo
g
ie
s
co
m
p
ar
ed
D
u
ra
ti
o
n
o
f
th
e
tr
ia
l
is
co
n
si
d
er
ed
t
P
ri
m
ar
il
y
b
as
ed
o
n
d
u
ra
ti
o
n
o
f
R
C
T
su
L
o
n
g
en
o
u
g
h
to
al
lo
w
p
ro
p
er
as
se
ss
m
en
t
o
f
d
if
fe
re
n
ce
s
in
h
ea
lt
h
o
u
tc
o
m
es
an
d
co
st
s
b
et
w
ee
n
th
e
as
se
ss
ed
h
ea
lt
h
te
ch
n
o
lo
g
y
an
d
th
e
co
m
p
ar
at
o
rs
S
h
o
u
ld
ca
p
tu
re
al
l
re
le
v
an
t
d
if
fe
re
n
ce
s
in
co
st
s
an
d
in
th
e
ef
fe
ct
s
o
f
h
ea
lt
h
tr
ea
tm
en
ts
an
d
re
so
u
rc
es
v
A. Angelis et al.
123
T
a
b
le
3
co
n
ti
n
u
ed
F
ra
n
ce
(H
A
S
/C
E
E
S
P
a
)
G
er
m
an
y
(I
Q
W
iG
)
S
w
ed
en
(T
L
V
)
E
n
g
la
n
d
(N
IC
E
)
It
al
y
(A
IF
A
)
N
et
h
er
la
n
d
s
(Z
IN
)
P
o
la
n
d
(A
O
T
M
iT
)
S
p
ai
n
(R
ed
E
T
S
/I
S
C
II
I
o
r
IC
P
)
T
h
re
sh
o
ld
s
T
h
re
sh
o
ld
s
N
o
th
re
sh
o
ld
(o
n
ly
el
ig
ib
il
it
y
th
re
sh
o
ld
to
co
n
d
u
ct
ec
o
n
o
m
ic
ev
al
u
at
io
n
)
E
ffi
ci
en
cy
fr
o
n
ti
er
(I
n
st
it
u
te
’s
o
w
n
ap
p
ro
ac
h
)
N
o
o
ffi
ci
al
th
re
sh
o
ld
;
5
0
%
li
k
el
ih
o
o
d
o
f
ap
p
ro
v
al
fo
r
IC
E
R
b
et
w
ee
n
€7
9
,4
0
0
an
d
€1
1
1
,7
0
0
£
2
0
,0
0
0
–
£
3
0
,0
0
0
p
er
Q
A
L
Y
;
E
m
p
ir
ic
al
:
£
1
2
,9
3
6
p
er
Q
A
L
Y
N
o
th
re
sh
o
ld
in
u
se
N
o
o
ffi
ci
al
th
re
sh
o
ld
3
9
G
D
P
p
er
ca
p
it
a
fo
r
IC
U
R
(Q
A
L
Y
)
o
r
IC
E
R
(L
Y
G
)
U
n
o
ffi
ci
al
:
€2
1
,0
0
0
–
€2
4
,0
0
0
/Q
A
L
Y
(r
ec
en
tl
y
p
ro
v
id
ed
b
y
S
E
S
C
S
w
to
th
e
S
p
an
is
h
M
o
H
)
S
o
u
rc
e
T
h
e
au
th
o
rs
(b
as
ed
o
n
li
te
ra
tu
re
re
v
ie
w
fi
n
d
in
g
s
an
d
ex
p
er
t
co
n
su
lt
at
io
n
)
C
E
A
C
o
st
-e
ff
ec
ti
v
en
es
s
an
al
y
si
s,
C
U
A
co
st
u
ti
li
ty
an
al
y
si
s,
C
M
A
co
st
m
in
im
iz
at
io
n
an
al
y
si
s,
Q
A
L
Y
q
u
al
it
y
ad
ju
st
ed
li
fe
y
ea
r,
L
Y
G
li
fe
y
ea
r
g
ai
n
ed
,
T
T
O
ti
m
e
tr
ad
e
o
ff
,
S
G
st
an
d
ar
d
g
am
b
le
a
In
F
ra
n
ce
,
ec
o
n
o
m
ic
ev
al
u
at
io
n
s
ar
e
u
n
d
er
ta
k
en
o
n
ly
fo
r
se
le
ct
ed
d
ru
g
s
w
it
h
ex
p
ec
te
d
si
g
n
ifi
ca
n
t
b
u
d
g
et
im
p
ac
t
b
A
te
m
p
la
te
fo
r
th
e
su
b
m
is
si
o
n
o
f
th
e
p
ri
ci
n
g
an
d
re
im
b
u
rs
em
en
t
(P
&
R
)
d
o
ss
ie
r
to
A
IF
A
is
in
p
ro
g
re
ss
c
F
o
r
th
e
ca
se
o
f
d
ru
g
s
at
ce
n
tr
al
le
v
el
ca
rr
ie
d
o
u
tb
y
IC
P
,c
o
m
p
ar
at
iv
e
ef
fi
ca
cy
/e
ff
ec
ti
v
en
es
s
is
ta
k
en
in
to
ac
co
u
n
t.
T
h
e
IC
P
re
ce
iv
es
th
e
so
ca
ll
ed
‘‘
In
fo
rm
e
d
e
P
o
si
ci
o
n
am
ie
n
to
T
er
ap
e´u
ti
co
’’
(T
h
er
ap
eu
ti
c
P
o
si
ti
o
n
in
g
re
p
o
rt
),
a
th
er
ap
eu
ti
c
as
se
ss
m
en
tc
o
n
d
u
ct
ed
b
y
th
e
S
p
an
is
h
M
ed
ic
in
es
A
g
en
cy
(A
g
en
ci
a
E
sp
an˜
o
la
d
el
M
ed
ic
am
en
to
)
b
as
ed
o
n
w
h
ic
h
co
n
fi
d
en
ti
al
d
is
cu
ss
io
n
s
ar
o
u
n
d
th
e
ap
p
ra
is
al
o
f
th
e
d
ru
g
s
ta
k
es
p
la
ce
b
u
t
w
h
ic
h
d
o
es
n
o
t
ta
k
e
in
to
co
n
si
d
er
at
io
n
co
st
-e
ff
ec
ti
v
en
es
s.
E
co
n
o
m
ic
ev
al
u
at
io
n
s
ar
e
m
ai
n
ly
ta
k
in
g
p
la
ce
fo
r
th
e
ca
se
o
f
n
o
n
-d
ru
g
te
ch
n
o
lo
g
ie
s
u
n
d
er
th
e
sc
o
p
e
o
f
R
ed
E
T
S
d
It
is
re
co
m
m
en
d
ed
to
u
se
in
d
ir
ec
t
m
et
h
o
d
s
fo
r
p
re
fe
re
n
ce
s
m
ea
su
re
m
en
t—
v
al
id
at
ed
q
u
es
ti
o
n
n
ai
re
s
in
P
o
li
sh
.
W
h
il
e
m
ea
su
ri
n
g
p
re
fe
re
n
ce
s
w
it
h
th
e
E
Q
-5
D
q
u
es
ti
o
n
n
ai
re
,
it
is
ad
v
is
ed
to
u
se
th
e
P
o
li
sh
u
ti
li
ty
st
an
d
ar
d
se
t
o
b
ta
in
ed
b
y
m
ea
n
s
o
f
T
T
O
e
S
u
rv
ey
s
o
r
p
re
v
io
u
sl
y
v
al
id
at
ed
H
R
Q
O
L
p
at
ie
n
t
su
rv
ey
s
f
In
cl
u
d
in
g
m
o
st
co
st
-e
ff
ec
ti
v
e,
le
as
t
ex
p
en
si
v
e,
m
o
st
ro
u
ti
n
el
y
u
se
d
,
an
d
n
ew
es
t
g
In
cl
u
d
in
g
m
o
st
co
st
-e
ff
ec
ti
v
e,
le
as
t
ex
p
en
si
v
e,
an
d
m
o
st
ro
u
ti
n
el
y
u
se
d
.
If
th
e
ef
fi
ci
en
cy
fr
o
n
ti
er
ap
p
ro
ac
h
is
u
se
d
as
p
ar
t
o
f
C
B
A
,
th
en
‘‘
al
l
re
le
v
an
t
co
m
p
ar
at
o
rs
w
it
h
in
th
e
g
iv
en
in
d
ic
at
io
n
fi
el
d
’’
m
u
st
b
e
co
n
si
d
er
ed
h
In
cl
u
d
in
g
m
o
st
co
st
-e
ff
ec
ti
v
e,
le
as
t
ex
p
en
si
v
e,
an
d
m
o
st
ro
u
ti
n
el
y
u
se
d
I
In
cl
u
d
in
g
m
o
st
co
st
-e
ff
ec
ti
v
e,
le
as
t
ex
p
en
si
v
e,
m
o
st
an
d
ro
u
ti
n
el
y
u
se
d
j
In
cl
u
d
in
g
m
o
st
co
st
-e
ff
ec
ti
v
e,
an
d
m
o
st
ro
u
ti
n
el
y
u
se
d
k
T
h
es
e
m
ig
h
t
in
cl
u
d
e
(1
)
m
o
st
fr
eq
u
en
tl
y
u
se
d
;
(2
)
ch
ea
p
es
t;
(3
)
m
o
st
ef
fe
ct
iv
e;
an
d
(4
)
co
m
p
li
an
t
to
th
e
p
ra
ct
ic
al
g
u
id
el
in
es
l
N
ee
d
s
ju
st
ifi
ca
ti
o
n
(e
sp
ec
ia
ll
y
if
so
ci
et
al
)
m
A
ls
o
co
m
m
u
n
it
y
o
f
st
at
u
to
ri
ly
in
su
re
d
,
p
er
sp
ec
ti
v
e
o
f
in
d
iv
id
u
al
in
su
re
rs
,
o
r
th
e
so
ci
et
al
p
er
sp
ec
ti
v
es
ar
e
p
o
ss
ib
le
n
S
o
ci
et
al
p
er
sp
ec
ti
v
e
is
n
o
t
m
an
d
at
o
ry
,
b
u
t
ca
n
b
e
p
ro
v
id
ed
in
se
p
ar
at
e
an
al
y
si
s
o
F
o
r
n
o
n
-d
ru
g
s
u
n
d
er
R
ed
E
T
S
,
a
sy
st
em
at
ic
li
te
ra
tu
re
re
v
ie
w
is
al
w
ay
s
co
n
d
u
ct
ed
p
F
o
r
n
o
n
-d
ru
g
s
u
n
d
er
R
ed
E
T
S
,
a
m
et
a-
an
al
y
si
s
m
ay
b
e
co
n
d
u
ct
ed
q
P
ri
ce
s
av
ai
la
b
le
in
th
e
O
ffi
ci
al
Jo
u
rn
al
o
f
th
e
It
al
ia
n
R
ep
u
b
li
c
(G
az
ze
tt
a
U
ffi
ci
al
e)
,
ac
co
u
n
ts
o
f
h
ea
lt
h
ca
re
ce
n
tr
es
,
th
e
fe
es
ap
p
li
ed
to
N
H
S
se
rv
ic
e,
sc
ie
n
ti
fi
c
li
te
ra
tu
re
/a
d
h
o
c
st
u
d
ie
s
r
In
cl
u
d
in
g
(1
)
li
st
o
f
st
an
d
ar
d
co
st
s,
(2
)
fo
rm
er
ly
p
u
b
li
sh
ed
re
se
ar
ch
,
(3
)
lo
ca
l
sc
al
es
o
f
ch
ar
g
es
,
(4
)
d
ir
ec
t
ca
lc
u
la
ti
o
n
s
It
is
cu
rr
en
tl
y
u
n
d
er
re
v
is
io
n
(A
O
T
M
iT
H
T
A
G
u
id
el
in
es
u
p
d
at
in
g
p
ro
ce
ss
)
an
d
m
ay
ch
an
g
e
so
o
n
t
A
d
d
it
io
n
al
lo
n
g
-t
er
m
ev
id
en
ce
co
ll
ec
te
d
th
ro
u
g
h
m
o
n
it
o
ri
n
g
re
g
is
tr
ie
s
u
S
ec
o
n
d
ar
y
h
o
ri
zo
n
s
in
cl
u
d
e
an
y
lo
n
g
er
n
ee
d
ed
d
ep
en
d
in
g
o
n
th
e
co
n
te
x
t
o
f
in
te
re
st
v
In
so
m
e
ca
se
s,
th
e
ti
m
e
h
o
ri
zo
n
w
il
l
h
av
e
to
b
e
ex
te
n
d
ed
to
th
e
in
d
iv
id
u
al
’s
en
ti
re
li
fe
sp
an
w
S
er
v
ic
io
d
e
E
v
al
u
ac
io´
n
y
P
la
n
ifi
ca
ci
o´
n
,
Is
la
s
C
an
ar
ia
s
Using health technology assessment to assess the value of new medicines...
123
inappropriate) [27, 28, 37, 38, 60, 74–77]. In Sweden, CBA
with WTP as an outcome measure can also be applied.
In France, up until now comparative assessment of
clinical benefit incorporating final endpoints as an outcome
measure acted as the preferred evaluation procedure.
However, economic analysis of selected drugs with
expected significant budget impact is continuously being
considered more formally, especially if its choice is justi-
fied and any methodological challenges (especially asso-
ciated with the estimation of QALYs) are successfully
addressed [27, 28, 41, 50, 51, 58]. The choice between
CEA and CUA depends on the nature of the expected
health effects (if there is expected significant impact on
HRQoL then CUA is used, otherwise CEA).
In Germany, economic evaluations are performed within
therapeutic areas and not across indications, thus, an effi-
ciency frontier approach of CBA using patient relevant
outcomes is the preferred combination of analysis
method and outcome measure [22, 27, 28, 58, 65]. Since
the introduction of the AMNOG, economic evaluations are
supposed to be conducted for cases when price negotiations
fail after the early benefit assessment and the verdict is
challenged by the technology supplier or the statutory
health insurer [65]. However, no such analysis has been
submitted so far and seems unlikely to ever happen because
the CBA would have to be re-evaluated by IQWiG, which
would hardly bring any better results [25].
In the Netherlands and Italy, the preferred type of eco-
nomic evaluation is CUA if the improvement in quality of
life forms an important effect of the drug being assessed, or
if this is not the case, a CEA [78, 79]. In Spain, any of the
four methods of analysis may be used (CMA, CEA, CUA
or CBA).
Types of clinical evidence considered
In relation to clinical evidence, all countries acknowledge
that randomised controlled head-to-head clinical trials are
the most reliable and preferred source of treatment effects
(i.e. outcomes), with data from less-rigorous study designs
being accepted in most study countries (England, France,
Germany, Sweden, Poland, Spain, Italy), e.g. when direct
RCTs for the comparators of interest are not available
[28, 53, 61].
Most agencies require systematic literature reviews to be
submitted by manufacturers as a source of data collection,
and carry out their own reviews. A meta-analysis of key-
clinical outcomes is recommended for pooling the results
together given the homogeneity of the evidence in Eng-
land, Italy, Netherlands and Poland [28, 53].
If evidence on effectiveness is not available through
clinical trials, France and the Netherlands allow for a
qualitative extrapolation based on efficacy data, with Spain
conducting quantitative extrapolation, and Sweden, Eng-
land, Italy and Poland applying both qualitative and
quantitative modelling. In Sweden, England and Nether-
lands, short-term clinical data are extrapolated also if data
on long-term effects are absent.
Resources/cost evidence
In terms of resources used, in addition to direct medical
costs, France and Sweden consider all relevant costs,
including direct non-medical and indirect costs, both for
patients and carers [27, 28]; however, only direct costs are
considered in the reference case analysis and incorporated
in the ICER in the case of France [50]. Germany also takes
into account informal costs and productivity gains sepa-
rately as a type of benefit, whereas England additionally
considers cost of social services.
Poland incorporates direct medical costs and direct
non-medical costs. In the Netherlands, the Health Care
Insurance Board’s ‘‘Manual for cost research’’ applies for
the identification, measurement and valuation of costs;
pharmacoeconomic evaluations need to include both
direct and indirect costs inside and outside the healthcare
system [78]. In Italy, it is recommended to include direct
costs; indirect costs can be taken into account in a sep-
arate analysis [25]. Spain incorporates both direct and
indirect costs (the latter on rare occasions), as well as
costs of labour production losses or lost time and informal
care costs, in the analysis [25, 58]. Finally, all countries
recommend the application of country-specific unit costs
[28].
Discounting and time horizon
In all study countries, both costs and benefits are dis-
counted [27, 58, 61, 74], and uncertainty arising due to
variability in model assumptions is investigated, usually in
the form of a sensitivity analysis. In Italy, information on
discounting is not available at the moment due to an update
in progress by AIFA [25]. In terms of a suitable time
horizon, none of the countries use an explicit time frame
but, instead, they adopt a period that is long enough to
reflect all the associated outcomes and costs of the treat-
ments being evaluated, including the natural course of the
disease [27, 80].
Acceptable ‘value for money’ thresholds
No explicit, transparent, or clearly defined cost-effective-
ness thresholds exist in any of the countries except for
England, Poland, and an academic proposal for Spain.
In line with the World Health Organization (WHO)
suggestions of two to three times the gross domestic
A. Angelis et al.
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product (GDP) per capita, a three times GDP per capita
threshold has been implemented in Poland. Generally, a
drug is deemed cost-effective by AOTMiT if cost per
QALY estimates are less than three times the GDP per
capita (but smaller than 70,000 PLN per QALY/LYG)
[25,81].
In Spain, a €21,000–€24,000 per QALY threshold was
recently provided by Servicio de Evaluacio´n y Planifi-
cacio´n Canarias (SESCS) to the Ministry of Health; how-
ever, this might not be actively adopted in practice [25].
In England, although evidence suggests the existence
of a threshold ranging somewhere between £20,000 and
£30,000 [44, 59, 75, 82], it is evident that such a
threshold range might not be strictly applied in practice,
with some products having a cost per QALY below these
ranges receiving negative coverage recommendations, and
other products above these ranges ending up with positive
recommendations [60, 83, 84]. Indeed, several studies
point towards the existence of a threshold range based on
which additional evidence on several factors is required
for the recommendation of technologies with an ICER of
above £20,000, and even stronger evidence of benefit in
combination with explicit reasoning required for the
coverage of technologies with an ICER above £30,000
[38, 39, 44, 53, 56, 85]. However, a more recent study
using data on primary care trust spending and disease-
specific mortality estimated an empirical based ‘‘central’’
threshold of £12,936 per QALY, with a probability of
0.89 of less than £20,000 and a probability of 0.97 to be
less than £30,000 [86].
In Germany, the efficiency frontier approach is used to
determine an acceptable ‘‘value for money’’, even though
this is not involved in the process of the initial rebate
negotiations. In Sweden, recent evidence suggested that the
likelihood of approval is estimated to be 50% for an ICER
between €79,400 and €111,700, for non-severe and severe
diseases respectively [87].
In the Netherlands, there is no formal threshold in place
but there have been some attempts to define one. The
€20,000 per life-year gained (LYG) threshold used in the
1990s to label patients with high cholesterol levels eligible
for treatment with statins has been mentioned in discus-
sions on rationing, but was never used as a formal threshold
for cost-effectiveness. The same was the case with a
threshold that the Council for Care and Public Health
wanted to implement based on criteria such as the GDP per
capita, in line WHO recommendations, which, for the
Netherlands, would translate into €80,000/QALY [71]. The
Council also suggested that the cost per QALY may be
higher for very severe conditions (a tentative maximum of
€80,000) than for mild conditions (where a threshold of
€20,000 or less may apply) [46], but none of the above was
ever implemented.
HTA outcomes and implementation
In all countries, assessment and appraisal of outcomes are
used mainly as a tool to inform coverage recommenda-
tions relating to the reimbursement status of the relevant
technologies; all countries use the results to inform pricing
decisions directly or indirectly. A summary of the types of
HTA outcomes and their implementation in the study
countries is presented in Table 4.
Timing and public availability
Generally, the time needed for the evaluation of a health
technology to be completed differs from country to country.
However, in line with the EU Transparency Directive, all
countries must have reached a decision on pricing and reim-
bursementwithin 180 days postmarketing authorisation [56].
In all countries, the final decision report is publicly available,
usually through the HTA agency’s website [12, 56], and the
policy implication of the evaluation outcome relates to the
pricing and reimbursement status of the technology: reim-
bursement (list), no reimbursement (do not list), or conditional
reimbursement (list with restrictions) [56, 68].
Policy implications
In France and Sweden, only drugs with additional thera-
peutic value can ‘‘obtain a higher reimbursement basis’’
[56]; in France, by assessing the evidence of the product’s
medical benefit or medical service rendered (SMR), the
improvement in medical benefit and added therapeutic
benefit (ASMR) are derived, which determine the reim-
bursement status and influence the price level of the pro-
duct respectively, whereas in Sweden the outcome of the
evaluation can also drive the price setting in addition to
coverage decisions [35, 36].
In Germany, the outcome of the clinical/economic
evaluation will be used mainly to inform the negotiation
between sickness funds and manufacturer on the price
premium. In England, reimbursement status has no direct
effects on price, but price indirectly affects the reim-
bursement status of the drug as it will have an impact on
the ICER. In the Netherlands, the positive outcome of an
HTA results in the inclusion of the medical technology in
the positive list [43]; in terms of the reimbursement deci-
sion, if the CEA for a new innovative drug is of
high quality, reimbursement will in principle not be denied
on the basis of cost-effectiveness, despite potentially rela-
tively high cost-per-QALY values [71]. Finally, in Italy, if
a reimbursement status is approved, the pricing is decided
simultaneously. If the reimbursement decision is negative,
the product will be put on the negative list and the price is
determined by the manufacturer (‘‘free pricing’’).
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Access restrictions
All countries apply access restrictions, usually relating to
specific indications or specific population sub-groups.
France mainly uses financial risk-sharing (price–volume)
agreements [56]. Sweden issues temporary decisions for
cases when there is insufficient certainty around the (clin-
ical) evidence [56], and risk sharing agreements may take
place to speed up the reimbursement process upon the
requirement of additional evidence following the review
[31], in addition to restricting access for specific sub-pop-
ulations. In England, major and minor restrictions exist: the
former relate to cases where the technology is indicated
only for second-line treatment (and beyond), or only for
specific sub-populations, and the latter relate to the need
for specialist supervision or treatment monitoring [39];
performance based agreements (also known as patient
access schemes) also exist, especially in regards to the use
of biologics and cancer drugs, according to which a pre-
specified clinical (endpoint) condition must be reached at a
specific post-assessment time point, i.e. response rules, for
the coverage of the technology to continue [88]. The
inclusion of expensive cancer drugs which are deemed
cost-ineffective in the cancer drugs fund (CDF) is indica-
tive of efforts to enable access to very costly medicines to
patients that need them on a selective basis.
In the Netherlands, the system of coverage with evi-
dence development (CED) for high cost and orphan inpa-
tient drugs was used extensively between 2006 and 2011.
Currently, financial-based agreements and performance-
based risk sharing agreements are considered as well. In
Poland, restrictions could be applied to a positive recom-
mendation, which can be either major, e.g. restricted to
specific subpopulations (monitoring of use), or minor, e.g.
requiring a lower price (so called Risk Sharing Schemes,
but cost sharing in practice) [25]. In Spain, MEAs are
concluded at the regional level. Price volume agreements
(PVAs) are usually applied to single new products where
the negotiated price is conditional on the expected number
of units sold.
Dissemination and implementation
Most countries employ dissemination procedures in order
to support the implementation of their decisions, including
prescribing guidelines and national drug formularies [43].
In France, since 2013, there is a public online drug data-
base allowing the general public to access data and docu-
ments on marketed drugs [89]. In Germany, IQWiG
prepares a variety of dissemination products besides the
dossier assessment including technical scientific reports
(and rapid reports where no commenting procedures take
place), but also public and user-friendly health information
and working papers on recent developments in the field,
including methodological aspects [52]. The dossier
assessment is provided by the G-BA, which can also issue
prescribing advice [25]. In Sweden, at least for the review
of products that are already on the positive list, informa-
tional material in the form of a fact sheet is produced
(possibly accompanied by supplementary information tak-
ing the form of a PowerPoint presentation and an FAQ
sheet), covering the analysis, the appraisal and the con-
clusion of the evaluation, distributed to the major stake-
holders on the date of the decision and about a week before
it becomes publicly available online [35, 36]. In England,
the NHS is legally obliged to implement NICE guidance
and fund the recommended technologies within 3 months
of the outcome of the decision [53, 60]. In Poland, since the
Reimbursement Act (issued in 2011, effective from 1
January 2012), drugs can be reimbursed under different
lists [25]. Pharmacy reimbursement includes prescribed-
only medicines available to patients through four main
categories of co-payment. Chemotherapy drugs are avail-
able in hospital settings free of charge. Other ‘‘regimen’’
programs are available, under which drugs for selected
diseases are reimbursed fully to strictly defined patient
populations whose eligibility is decided by appropriate
clinician committees.
Appeal mechanisms and review of decisions
Most countries have appeal mechanisms in place in case
of dissent and they all revise their decisions either
according to fixed time schedule or on a rolling basis
[56, 61]; in France, the drug registration is subject to
renewal every five years and a drug may also be subject
to post-registration studies. Sweden re-evaluates its old
reimbursement list and both Sweden and England may
revise technologies once new evidence becomes available.
On average, positive recommendations (with or without
restrictions) account for approximately 90% of NICE’s
appraisals [90].
Although it appears that revisions were taking place
systematically after four years for in-patient drugs and
on an ad hoc basis for out-patient drugs [42, 56], more
recent evidence suggests that, in practice, the process is
irregular and providers that have no adequate reim-
bursement due to a new innovation will ask the Dutch
healthcare authority for a revision of reimbursement.
The agency then investigates if a revision is reasonable
and what the new reimbursement should be [25]. In
Italy, the negotiation process leads to a 2-year, confi-
dential, renewable contract between AIFA and the
manufacturer [25]; a possible revision is feasible on the
grounds of a new product exceeding the original forecast
of a company.
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Discussion
In all study countries, HTA agencies have an autonomous
function. The evaluation process of medical technologies
typically involves an initial assessment of evidence con-
ducted by technical groups, followed by the appraisal of
the assessed evidence from an expert committee that is
producing reimbursement and coverage recommenda-
tion(s) for the final decision body, which can be either the
payer (e.g. MoH, HIF), or the HTA agency itself.
In addition to the comparative assessment of clinical
benefit, most countries implement a type of economic
evaluation (mainly CUA or CEA) as the main analytical
method to determine the value of new technologies, with
the preferred health gain measure usually being the QALY,
or alternative patient-relevant (if not final) outcomes. Both
direct preference-based elicitation techniques (e.g. TTO,
SG) and indirect multi-attribute classification systems (e.g.
EQ-5D and HUI3) are used to elicit utility scores either
from patients or the general population. The debate around
preferred health gain measures is strong and often contra-
dictory across jurisdictions. For example, while NICE in
England favours the use of the QALY, IQWiG in Germany
strongly opposes its use on the grounds that it does not
reflect patient-level utilities being the ones that actually
matter, rather than population-based utilities [25].
The evaluation (assessment and appraisal) outcome is
used mainly as an aid to make coverage recommendations
in relation to the reimbursement status of medical tech-
nologies, but the analysis outcomes are also used to influ-
ence pricing decisions as well (although this is done only
indirectly in England). Access restrictions for sub-popula-
tions or sub-indications, possibly through the application of
risk-sharing agreements, have become common practice
across many jurisdictions. Information material is often
disseminated by the HTA agencies to a range of stake-
holder groups; the implementation of agencies’ recom-
mendations is usually taking the form of prescribing
guidelines and inclusion into drug formularies. Technology
suppliers across all jurisdictions have the option of dissent/
appeal and revision of recommendations is taking place
either over a standard period of time or when new evidence
becomes available.
Our results show that additional value concerns going
beyond economic evaluation or clinical benefit assess-
ment are captured to a different extent or included in the
evaluation process as criteria that may help to explain
some of the heterogeneity observed in coverage recom-
mendations and decision-making.
Overall, all countries assess similar types of evidence;
however, the specific endpoints used, their level of provi-
sion and requirement, the way they are incorporated (e.g.
explicitly vs. implicitly) and their relative importance vary
across countries. The same holds for the interpretation of
the submitted evidence by HTA agencies [7]. Overall, the
main evidence assessed could be divided into six clusters
of information: (1) burden of disease, (2) therapeutic and
safety impact, (3) innovation level, (4) socioeconomic
impact, (5) efficiency considerations, and (6) other sources
of evidence and criteria.
Conceptual and methodological limitations in value
assessment
Current value assessment (VA) approaches mainly con-
sider comparative clinical efficacy in combination with
clinical cost-effectiveness techniques, while increasingly
incorporating real world data after a new drug has entered
the market, thus essentially reflecting comparative effec-
tiveness and efficiency. However, there is considerable
subjectivity in the criteria selection used to interpret evi-
dence and determine product value, notably which metrics
can be used to measure efficacy and effectiveness, what
type of costs need to be considered, and, very importantly,
how to account for other key dimensions of value.
Most VA approaches examine the efficacy/effective-
ness, or cost-effectiveness of new interventions by mostly
addressing only a partial dimension of ‘overall value’ in a
systematic and explicit manner that relates mainly to
‘scientific value judgments’ (ScVJ) of their therapeutic
aspect (e.g. safety, efficacy, effectiveness), possibly in
relation to cost. However, as many HTA agencies have
recognised (at least indirectly), the value of new medical
technologies is multi-dimensional, and not only limited to
clinical benefit and cost. In addition to commonly used
ScVJ, which are based solely on ‘‘scientific’’ evidence
relating to clinical cost-effectiveness and ICERs, other
‘‘social’’ value factors (social value judgements—SoVJ),
falling under the information clusters of burden of disease,
innovation level and socioeconomic impact, also play a
definitive role in the deliberative process and, ultimately, in
decision-making; however, there is little, if any, evidence
on how SoVJ are captured formally in the appraisal process
across settings.
In most settings, the absence of clarity on the use of
SoVJ, including their interplay with ScVJ, and their influ-
ence on coverage recommendations, remains unknown.
SoVJs are usually considered implicitly by HTAs or deci-
sion-makers mostly on an ad-hoc basis. In most cases it is
not known what their relative importance is, and what trade-
offs HTA agencies are willing to make. As a result, the
concept of ‘overall value’ remains elusive, given that mul-
tiple evaluation criteria apply across different settings, with
differential intensity and in a non-systematic manner.
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Policy implications and ways forward
Following the technical review of policy initiatives and
opportunities for collaboration and research for access to
new medicines in Europe, WHO proposes far more
extensive use of HTA in decision-making [91]. However,
for this to take place, a more holistic perspective and
coordinated action would be needed.
Decision-makers, as well as other stakeholders, need
clear, comprehensive and transparent ways of assessing
clinical and economic benefit and the impact those new
treatments have, from a wider socio-economic perspective,
in order to make rational decisions about priority setting.
Not having such methods creates a conceptual, method-
ological and policy gap. Appropriate adaptations of current
methodologies, or development of new transparent con-
ceptual frameworks, seem to be needed.
NICE in England is one of the forerunner agencies in
acknowledging, formalising and creating a methodological
landscape for SoVJ, which include, first, the burden of dis-
ease the treatment addresses, hence the clinical and policy
importance of the health topic under consideration; second,
the cost impact on resources from a societal perspective;
third, policy objectives relating to the long-term benefits of
innovation [92–94], and, in general, the broader balance
between benefits and costs. The existing influence of disease
severity could be illustrated in the context of EoL treat-
ments, where QALYs gained for terminal illnesses have a
greater weight [95], on the grounds that society places a
special value on extending the lives of the terminally ill [96].
Decision makers have been exploring new ways of consid-
ering additional value parameters, while highlighting the
need for ‘‘a broader and more transparent assessment’’
methodology, suggesting a move towards value-based
assessment [97, 98]. A comparable approach highlighting
the broader societal implications of introducing a new
technology, addressing considerations of need, equity and
human dignity, are also present explicitly in the case of the
Swedish TLV. Despite the explicit nature of these broader
considerations, it is unclear what their influence is in shaping
VAs and coverage recommendations.
Aspects of HTA shortcomings have also been reflected
by various recent initiatives seeking to establish ‘‘value
frameworks’’ aiming to aid pricing and clinical practice
decisions by considering a variety of parameters for the
assessment of value, possibly in relation to costs. Most of
that work has been led by professional associations seeking
clarity on the determinants of value and their relative
importance to different stakeholders [99–103]. However,
attention should be paid to their methodologies, for recom-
mendations to be robust and to avoid misguided decisions
[104]. All these initiatives have attempted to adopt multi-
criteria evaluation approaches, albeit in a very simplified and
relatively abstract manner. Other approaches embedded in
decision analysis could address benefit-risk assessment
considerations of health care interventions [105, 106].
Considering the limitations highlighted by this systematic
review in the context of HTA as it is practised currently, it
looks as though multi-criteria decision analysis methods
could be explored to capture the value of new medical
technologies in a holistic manner and, through this, facilitate
HTA decision-making processes in a spirit of transparency,
comprehensiveness, and flexibility [107, 108].
The heterogeneity in VA systems across Europe, which
also results in significant difference in coverage recom-
mendations across settings based on how HTA agencies
perceive or interpret evidence and the associated uncer-
tainties, has recently acquired another important dimen-
sion; in September 2016, the European Commission
outlined its thoughts to strengthen EU cooperation on HTA
[109]. The Commission’s vision includes several options,
ranging from voluntary long-term cooperation to coopera-
tion on the production of full joint HTA reports. While it is
very premature to speculate what the likely outcome of this
initiative is going to be beyond 2020, when the current
Joint Action 3 ends, the Commission’s desired course of
action seems to be in favour of greater collaboration
amongst HTA agencies. Whatever the form of collabora-
tion, member states will undoubtedly contend that the
principle of subsidiarity will need to hold. This implies that
member states will continue to exercise control on
appraisals and coverage recommendations, but assessment
could be done through some form of collaborative
arrangement (jointly, via mutual recognition, or otherwise).
If so, the precise criteria that are acceptable across member
states will need to be clarified and explicitly incorporated
into the assessment process. The current heterogeneity in
coverage recommendations, which results partly from dif-
ferences in methods applied in the assessment phase, and
special considerations/social value judgements applied in
the appraisal phase, may need to be addressed by recog-
nising the relative importance of the latter in the assess-
ment phase. This would provide greater steering to member
states during the appraisal phase when they seek to make
final decisions on coverage. It will also require significant
debate in order to come to a joint understanding on the
different criteria and their relative importance that can be
used in and inform the assessment phase beyond costs and
effects.
Conclusion
The study highlights a number of significant similarities
but also considerable differences in the practices, processes
and policies of VA for new medicines across eight study
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countries in Europe. These differences exist because of
different national priorities between countries, but also
because of different processes and methodological frame-
works adopted for the elicitation of decision-makers’
preferences. Overall, there is considerable ambiguity with
regards to what additional value criteria to incorporate,
how to establish their relative importance, and whose
preferences to consider. Currently, all these decisions are
subject to decision-makers’ discretion, but are in most
cases exemplified in a less than transparent way, potentially
resulting in some form of bias.
Procedures characterized by greater transparency or
clarity in terms of value criteria used and a higher degree of
comprehensiveness and methodological robustness could
lead to more rational evidence-based decision making,
contributing to more efficient resource allocation and,
potentially, higher societal welfare, while also raising
public confidence and fairness in terms of homogeneity and
consistency of decision outcomes.
The limitations of the current VA methodologies and the
identified conceptual and policy gaps suggest that there is a
need for methodological approaches that encompass multiple
evaluation criteria explicitly, so that value can be an explicit
function of a number of dimensions beyond those that are
currently explicitly and sytematically captured. This is
increasingly becoming imperative in the context of European
collaboration, particularly if some form of joint assessment at
EU level is likely to emerge beyond 2020. Decision analysis
and multi-criteria evaluation approaches could potentially
provide the foundation formeasuring and eliciting the value of
new medicines and technologies as they provide a compre-
hensive alternative for quantitative modelling.
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